EXECUTIVE TEAM
Lawrence A. Kenyon
Interim Chief Executive Officer & Chief Financial Officer
Mr. Kenyon has served as our Interim Chief Executive Officer since December 2024 and the Company’s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as the Company’s President and CEO from August 2018 to July 2021. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company, or Par. Prior to joining Par, Mr. Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, or Alfacell, from January 2007 through February 2009 and also served at various times during this period as Alfacell’s Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell’s board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006.
Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin-Whitewater and is a Certified Public Accountant in Illinois.
Jeff Evanson
Chief Commercial Officer
Mr. Evanson has served as our Chief Commercial Officer since November 2018. Mr. Evanson joined Outlook Therapeutics from Scott Three Consulting where he was the Founder and President. Previously he was a Managing Director in the Life Science Practice of Navigant from 2014 to 2018. He joined the firm in September of 2014 from Novartis (Alcon) where he was the Vice President and Global Commercial Head of the Pharmaceutical Franchise. During his time at Alcon, he was responsible for all aspects of strategy, portfolio (both internal and external opportunities), global brands, launches and campaigns. Mr. Evanson has extensive experience with the ophthalmology and retina landscape including sustained delivery, drug/device combination and diagnostics within the dry eye, glaucoma, retina and allergy eye health markets.
Prior to Novartis, Mr. Evanson spent 10 years at Medtronic in a variety of pre-commercialization and post-commercialization roles. He has led programs from Opportunity Assessment through to Global Launch Plans and Life Cycle Management. These responsibilities allowed Mr. Evanson direct experience with the US FDA and the US Centers for Medicare and Medicaid Services. Mr. Evanson also has experience in Pharmaceutical Sales and Sales Training.
Jeff received his MBA from the University of Minnesota (2001) and a BA in Chemistry from the University of St. Thomas in St. Paul Minnesota (1991). He served as a two-term Board Member of Gillette Children’s Hospital in St. Paul, Minnesota, from 2008 to 2014 and currently is on the Board of Directors of Children’s HeartLink.
